Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia

Evinacumab, an angiopoietin‐like protein 3 (ANGPTL3) inhibitor, has been shown to significantly reduce low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). This work characterized the population pharmacokinetics (PK)/pharmacodynamics (PD) of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Xia, Sale, Mark, Yang, Feng, Zhang, Yi, Davis, John D., Al‐Huniti, Nidal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592514/
https://www.ncbi.nlm.nih.gov/pubmed/34585515
http://dx.doi.org/10.1002/psp4.12711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592514/
https://www.ncbi.nlm.nih.gov/pubmed/34585515
http://dx.doi.org/10.1002/psp4.12711

Ejemplares similares